64th Annual Meeting of the American Association for the Study of Liver Diseases (The Liver Meeting)

64th Annual Meeting of the American Association for the Study of Liver Diseases (The Liver Meeting) | AASLD 2013

Billed as "the single most influential and wide-ranging dialogue about liver disease in the world," The Liver Meeting® is "the premier Annual Meeting in the science and practice of hepatology, including the latest findings on new drugs, novel treatments, and the results from pilot and multicenter studies."

Conference Coverages

Hyponatremia Produces Poor Outcomes in Acute-on-Chronic Liver Failure
Hyponatremia Produces Poor Outcomes in Acute-on-Chronic Liver Failure
Drawing upon data from a large European study, Andrés Cárdenas, MD, reported an association between hyponatremia and acute-on-chronic liver failure (ACLF) during a poster session at the 2013 annual meeting of the American Association for the Study of Liver Diseases held November 1-5, 2013, in Washington, DC.
Hyponatremia Correction in Cirrhosis May Improve Cognition, Reduce Caregiver Burden
Investigating the association between hyponatremia and cognition in patients with cirrhosis, Jasmohan Bajaj, MD, and colleagues from Virginia Commonwealth University presented results showing reduced brain edema, better quality of life (QOL), and less caregiver burden with the use of the aquaretic tolvaptan.
Investigational Antiviral Offers Benefit in Patients Co-Infected with Hepatitis C, HIV
A novel direct-acting antiviral (DAA) targeting a protein associated with hepatitis C (HCV) also has antiviral activity against HIV-1 and shows benefit in co-infected individuals when added to pegylated interferon and ribavirin treatment (PR).
12 Weeks Post-Treatment Is Appropriate Endpoint for Measuring Response to Hepatitis C Regimen
Emerging data from a clinical trial on triple direct-acting antiviral (DAA) therapy plus ribavirin (RBV) in hepatitis C (HCV) genotype 1 (GT1) patients shows that the low rate of relapse during and after treatment leads to high concordance rates between measurements of sustained viral response (SVR) at 4, 12, and 24 weeks post-treatment.
Long-Term Tenofovir Disoproxil Fumarate Treatment Well Tolerated in Hepatitis B
Sustained viral response (SVR) without resistance or safety issues was reported among chronic hepatitis B (HBV) patients taking tenofovir disopoxil fumarate (TDF) therapy over a 7-year period.
Novel Interferon-Free Regimen for Hepatitis C Produces High Treatment Adherence, Sustained Viral Response
High medication adherence and sustained viral response (SVR) has been reported in hepatitis C (HCV) patients taking an interferon-free, short-duration, oral regimen of ribavirin (RBV) combined with 3 direct-acting antivirals (DAAs) that are currently in phase 2b/3 clinical trials.
Extended Triple Therapy After Liver Transplant Improves Hepatitis C Virologic Response, But at a Cost of Toxicity
Triple therapy consisting of a protease inhibitor combined with pegylated interferon alfa and ribavirin (PR) may increase sustained viral response (SVR12), but it may be more difficult to tolerate than PR therapy alone.
Interdisciplinary Primary Care Model Achieves Sustained Virologic Response in Hepatitis C
As the worldwide disease burden increases and the need for expanded access to care rises concomitantly, primary care clinics utilizing an interdisciplinary staffing model offer a promising alternative to treating patients with hepatitis C (HCV).
Initiating Treatment for Hepatitis C Genotype 1 Before Progression to Cirrhosis May Reduce Liver Complications
Watchful waiting in patients with chronic hepatitis C (HCV) genotype 1 infection may increase the number of advanced liver disease cases, according to a poster presented at the 2013 American Association for the Study of Liver Disease (AASLD) meeting held in Washington, DC.

Most Popular


$vacMongoViewPlus$ $vAR$